Early data suggests this can cut the risk of recurrence in half for certain patients. In an era of "influencers" and viral health trends, Dr. Jarushka Ross represents the opposite: the quiet, rigorous, data-driven clinician who sits with a terrified family at 6 PM on a Friday.
While other researchers were celebrating the remission rates, Ross noticed the collateral damage. Patients whose lungs were clearing up were suddenly in emergency rooms with inflamed colons, arthritic joints, or, most frighteningly, swollen brains. This is Ross’s signature contribution to the field. She became the world’s leading expert on immune-related adverse events (irAEs) . jarushka ross
You may not have seen her on a primetime talk show, but inside the walls of Dublin’s Beaumont Hospital and the global corridors of the International Association for the Study of Lung Cancer (IASLC) , she is something of a rock star. And her specialty? The most stigmatized, aggressive, and historically hopeless of all major cancers: lung cancer. Ross’s journey is not the typical tale of a straight-A student following a linear path. A graduate of Trinity College Dublin, she did something many Irish-trained doctors are afraid to do—she left the green shores for the brutal, brilliant crucible of American medicine. Early data suggests this can cut the risk
In the high-stakes world of oncology, where statistics often feel cold and conversations are measured in survival curves, there is a rare breed of physician who speaks two languages fluently: the language of molecular biology and the language of human hope. Dr. Jarushka Ross (often known in research as Jarushka Naidoo) is one of those people. She became the world’s leading expert on immune-related